EU and US could reach trade deal this weekend - Reuters
Sight Sciences , Inc. (NASDAQ:SGHT) Director and significant shareholder Staffan Encrantz recently acquired a substantial amount of the company’s common stock. According to a recent SEC filing, Encrantz purchased shares over several days, totaling an investment of approximately $381,957. The timing appears strategic, as InvestingPro data shows the stock has gained nearly 14% in the past week, though trading at $4.20, still well below its 52-week high of $8.45.
On June 4, Encrantz acquired 21,674 shares at a weighted average price of $4.172 per share. The following day, he purchased an additional 40,951 shares, with prices ranging from $4.19 to $4.295 per share, averaging at $4.244. On June 6, Encrantz added another 27,900 shares to his holdings, priced between $4.20 and $4.245, with an average of $4.22 per share. These purchases come as the company maintains a strong balance sheet, with more cash than debt and a healthy current ratio of 10.47.
These transactions reflect Encrantz’s continued confidence in Sight Sciences, as he maintains a substantial stake in the company. As of the latest filing, he holds direct ownership of 1,377,964 shares, with additional shares held indirectly through trusts and investment funds. For deeper insights into SGHT’s valuation and growth potential, including 10 additional exclusive ProTips, check out the comprehensive research report available on InvestingPro.
In other recent news, Sight Sciences Inc. reported its first-quarter 2025 earnings, revealing a net loss per share of $0.28, which was below the expected $0.23. The company’s revenue for the quarter was $17.5 million, also falling short of the forecasted $18.4 million. Despite these results, Sight Sciences maintained its revenue guidance for the year 2025. In a strategic move, the company is shifting its manufacturing out of China to mitigate the impact of tariffs, a transition expected to take over nine months. Needham maintained a Hold rating on Sight Sciences, acknowledging the company’s adaptation to market changes but opting for caution. Additionally, Sight Sciences appointed Gerhard F. Burbach to its Board of Directors and ratified Deloitte & Touche LLP as its independent auditor for the fiscal year ending December 31, 2025. The company also conducted its annual meeting, electing three Class I directors to serve until 2028. These developments reflect Sight Sciences’ ongoing efforts to navigate financial challenges and strategic shifts in its operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.